Secretin - Innovate Biopharmaceuticals

Drug Profile

Secretin - Innovate Biopharmaceuticals

Alternative Names: INN-329; RG 1068; SecreFlo

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Repligen
  • Developer Repligen Corporation
  • Class Antipsychotics; Gastrointestinal hormones; Neuropeptides; Peptide diagnostics; Peptide hormones
  • Mechanism of Action Emission-computed tomography enhancers; Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic disorders
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Pancreatic disorders
  • No development reported Obsessive-compulsive disorders; Pancreatic cancer
  • Discontinued Autistic disorder; Schizophrenia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-0 development in Pancreatic-cancer(Diagnosis) in USA (IV)
  • 15 Mar 2016 Biomarkers information updated
  • 07 Jan 2015 No development reported - Phase-III for Pancreatic disorders (Diagnosis) and Diagnostic imaging in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top